

## Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-Bclx<sub>L</sub> strategies through Mcl-1 down-regulation


## SUPPLEMENTARY MATERIALS



Supplementary Data 1: Inhibition of Mcl-1 by CAI does not involve CamKII and AMPK. Cells were treated with increasing doses of 5  $\mu$ M CAI for 48h for IGROV1-R10 and 72h for OVCAR3 and SKOV3. The effect of CAI treatment on P-CamKII, P-AMPK, AMPK, 4E-BP1 and Mcl-1 was assessed by western blot.



**Supplementary Data 2: Inhibition of Mcl-1 by YM58483 does not involve CamKII and AMPK.** Cells were treated with YM58483 (15 μM for 48h for IGROV1-R10 cells, 15 μM for 72h for OVCAR3 cells and 20 μM for 72h for SKOV3 cells). The effect of YM58483 treatment on P-CamKII, P-AMPK, AMPK, 4E-BP1 and Mcl-1 was assessed by western blot.



**Supplementary Data 3: CAI combined with siRNA targeting Bcl-xL leads to apoptosis in ovarian carcinoma.** Cells were transfected with anti-Bcl-x<sub>L</sub> siRNA for 24h for IGROV1-R10 and OVCAR3 or 48h for SKOV3. Then cells were treated with 5  $\mu$ M CAI for 48h for IGROV1-R10 and 72h for OVCAR3 or SKOV3. Mcl-1 and Bcl-x<sub>L</sub> expressions and PARP and caspase 3 cleavages were studied by western blot.